The specialist developer and distributor of computerised neuropsychological tests including those enabling the early detection of dementia, last month completed a placing raising gross proceeds of £1.25m. The company’s core customer base comprises leading academic research institutes and pharmaceutical and biotechnology companies. The development focus is now shifting to high volume measurement which will facilitate penetration into the healthcare market which is currently the com
18 May 2016
A positive assessment
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
A positive assessment
Cambridge Cognition Holdings Plc (COG:LON) | 52.0 0 0.0% | Mkt Cap: 18.3m
- Published:
18 May 2016 -
Author:
Derren Nathan -
Pages:
21
The specialist developer and distributor of computerised neuropsychological tests including those enabling the early detection of dementia, last month completed a placing raising gross proceeds of £1.25m. The company’s core customer base comprises leading academic research institutes and pharmaceutical and biotechnology companies. The development focus is now shifting to high volume measurement which will facilitate penetration into the healthcare market which is currently the com